First inhaled gene therapy tested for rare lung disorder
Disease control
Completed
This early-stage study tested the safety of an experimental inhaled medicine called RCT1100 in seven adults with a rare genetic lung disease called Primary Ciliary Dyskinesia (PCD). The goal was to see if the treatment was safe and to gather initial data on whether it could help …
Phase: PHASE1 • Sponsor: ReCode Therapeutics • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC